| 1. |
Clark, A. J. (1937) General pharmacology, in Heffter’s Handbuch der Experimentallen Pharmakologie (Clark, A. J., ed.), Vol. 4, Springer-Verlag, Berlin, pp. 1–223.
|
| |
| 2. |
Leff, P. (1995) The 2-state model of receptor activation. Trends Pharmacol. Sci.
16, 89–97.
|
| |
| 3. |
Bond, R. A., Leff, P., Johnson, T. D., Milano, C. A., Rockman, H. A., McMinn, T. R., et al. (1995) Physiological effects of
inverse agonists in transgenic mice with myocardial over-expression of the beta(2)-adrenoceptor. Nature
374, 272–276.
|
| |
| 4. |
Stephenson, R. P. (1956) A modification of receptor theory. Br. J. Pharmacol.
11, 379–393.
|
| |
| 5. |
Furchgott, R. F. (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation
constants of receptor-agonist complexes, in Advances in Drug Research (Harper, N. J. and Simmonds, A. B.,eds.), Vol. 3, Academic Press, New York, pp. 21–55.
|
| |
| 6. |
Black, J. W. and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond.
220, 141–162.
|
| |
| 7. |
Park, H. S. and Hourani, S. M. O. (1999) Differential effects of adenine nucleotide analogues on shape change and aggregation
induced by adenosine 5′-diphospbate (ADP) in human platelets. Br. J. Pharmacol.
127, 1359–1366.
|
| |
| 8. |
Hall, D. A. and Hourani, S. M. O. (1993) Effects of analogs of adenine nucleotides on increases in intracellular calcium mediated
by P2T-purinoceptors on human blood platelets. Br. J. Pharmacol.
108, 728–733.
|
| |
| 9. |
Hourani, S. M. O. (2001) Discovery and recognition of purine receptor subtypes on platelets. Drug Devel. Res.
52, 140–149.
|
| |
| 10. |
Palmer, R. K., Boyer, J. L., Schachter, J. B., Nicholas, R. A. and Harden, T. K. (1998) Agonist action of adenosine triphosphates
at the human P2Y(1) receptor. Mol. Pharmacol.
54, 1118–1123.
|
| |
| 11. |
Zhang, F. L., Luo, L., Gustafson, E., Lachowicz, J., Smith, M., Qiao, X. D., et al. (2001) ADP is the cognate ligand for the
orphan G protein-coupled receptor SP1999. J. Biol. Chem.
276, 8608–8615.
|
| |
| 12. |
Uneyama, C., Uneyama, H., and Akaike, N. (1993) Cytoplasmic Ca2+ oscillation in rat megakaryocytes evoked by a novel type of purinoceptor. J. Physiol.
470, 731–749.
|
| |
| 13. |
Somasundaram, B. and Mahaut-Smith, M. P. (1994) Three cation influx currents activated by purinergic receptor stimulation
in rat megakaryocytes. J. Physiol.
480, 225–231.
|
| |
| 14. |
Mahaut-Smith, M. P., Ennion, S. J., Rolf, M. G., and Evans, R. J. (2000) ADP is not an agonist at P2X1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br. J. Pharmacol.
131, 108–114.
|
| |
| 15. |
Gaddum, J. H. (1937) The quantitative effects of antagonistic drugs. J. Physiol.
89, 7P–9P
|
| |
| 16. |
Arunlakshana, O. and Schild, H. O. (1959) Some quantitative uses of drug antagonists. Br. J. Pharmacol.
14, 48–58.
|
| |
| 17. |
Kenakin, T. P. (1982) The Schild regression in the process of receptor classification. Can. J. Physiol. Pharmacol.
60, 249–265.
|
| |
| 18. |
Hall, D. A. and Hourani, S. M. O. (1994) Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate
cyclase induced by adenosine 5′-diphosphate in human platelets. Biochem. Pharmacol.
47, 1013–1018.
|
| |
| 19. |
Hourani, S. M. O., Hall, D. A., and Nieman, C. J. (1992) Effects of the P2-purinoceptor antagonist, suramin, on human platelet-aggregation
induced by adenosine 5′-diphosphate. Br. J. Pharmacol.
105, 453–457.
|
| |
| 20. |
Cusack, N. J. and Hourani, S. M. O. (1982) Adenosine 5′-diphosphate antagonists and human platelets — no evidence that aggregation
and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br. J. Pharmacol.
76, 221–227.
|
| |
| 21. |
Gaddum, J. H. (1945) Lognormal distributions. Nature
156, 463–466.
|
| |
| 22. |
Leff, P., Prentice, D. J., Giles, H., Martin, G. R., and Wood, J. (1990) Estimation of agonist affinity and efficacy by direct,
operational model-fitting. J. Pharm. Methods
23, 225–237.
|
| |
| 23. |
Prentice, D. J. and Hourani, S. M. O. (1997) Information in agonist curve shape for receptor classification, in Ann. N.Y. Acad. Sci., Vol. 812, pp. 234–235.
|
| |
| 24. |
Cheng, Y. C. and Prusoff, W. H. (1973) Relationship between the inhibition constant (KI) and thc concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol.
22, 3099–3108.
|
| |
| 25. |
Lazareno, S. and Birdsall, N. J. M. (1993) Estimation of competitive antagonist affinity from functional inhibition curves
using the Gaddum, Schild and Cheng-Prusoff equations. Br. J. Pharmacol.
109, 1110–1119.
|
| |
| 26. |
Kenakin, T. P. (1997) Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed., Raven Press, New York.
|
| |
| 27. |
Kenakin, T. P. and Angus, J. A. (2000) The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems. Handbook of Experimental Pharmacology, 148, Springer-Verlag, Berlin Heidelberg.
|
| |
| 28. |
Neubio, R.R., Spedding, M., Kenakin, T., and Christopoulos, A. (2003) International Union of Pharmacology Committee on Receptor
Nomenclature and Drug Classification. XXXVIII Update on Terms and Symbols in Quantitative Pharmacology. Pharmacol. Rev.
55, 597–606.
|
| |